Phase 3 DUO-O (1130 patients, newly diagnosed non-tBRCAm advanced ovarian cancer): durvalumab with olaparib maintenance improved PFS versus control (HR 0.63; median 24.2 vs 19.3 months; HR 0.49 if HRD-positive). Interim OS did not differ (HR 0.95).
RCTn = 1,130 patients
Harter et al. Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer